CTX-009 (ABL001) + Paclitaxel + Irinotecan
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
P1b: Advanced Solid Tumors
Conditions
P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer
Trial Timeline
Jun 22, 2020 → Jan 9, 2025
NCT ID
NCT04492033About CTX-009 (ABL001) + Paclitaxel + Irinotecan
CTX-009 (ABL001) + Paclitaxel + Irinotecan is a phase 1/2 stage product being developed by Compass Therapeutics for P1b: Advanced Solid Tumors. The current trial status is terminated. This product is registered under clinical trial identifier NCT04492033. Target conditions include P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer.
Hype Score Breakdown
Clinical
9
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04492033 | Phase 1/2 | Terminated |